TESARO is a biopharmaceutical company focused on providing therapies to people facing cancer. Co.'s primary focus is to develop treatments for tumors using various approaches, including small molecules and immuno-oncology antibodies, as monotherapies or in combinations. Co.'s products are: ZEJULA® (niraparib), which is for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI® (rolapitant), a neurokinin, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Co. is evaluating its immuno-oncology anti-tumor agents in combination studies with niraparib and other anti-tumor agents. We show 27 historical shares outstanding datapoints in our TSRO shares outstanding history coverage, used to compute TSRO market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing TSRO market cap history over the course of time is important for investors
interested in comparing TSRO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of TSRO versus a peer is one thing; comparing
TSRO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like TSRO can fluctuate over the course of history.
With this page we aim to empower investors researching TSRO by allowing them to research the TSRO market cap history. |
Free TSRO Email Alerts:
Video: The Importance of Market Cap
